The biochemistry of drug metabolism - An introduction: Part 6. Inter-individual factors affecting drug metabolism

Chemistry and Biodiversity

Volumn 5, Issue 12, 2008, Pages 2465-2578

  Krämer, Stefanie D ^a   Testa, Bernard ^b  

^a ETH ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (PYRIDIN 4 YL) 1H [1,2,4]TRIAZOL 3 YL]PYRIDINE 2 CARBONITRILE; 5 BUTYL 7 (3,4,5 TRIMETHOXYBENZAMIDO)PYRAZOLO[1,5 A]PYRIMIDINE; 5 BUTYL 7 [(3,4,5 TRIMETHOXYBENZOYL)AMINO]PYRAZOLO[1,5 A]PYRIMIDINE; ALDEHYDE DEHYDROGENASE; ANALGESIC AGENT; COTININE; CYTOCHROME P450; DEBRISOQUINE; DESIPRAMINE; DEXTROMETHORPHAN; DIGOXIN; EPOTHILONE D; FYX 051; GLUCURONIDE; ISOSORBIDE; LEVODOPA; MEPHENYTOIN; METRONIDAZOLE; MIANSERIN; NICOTINE; NORTRIPTYLINE; OLANZAPINE; PROPRANOLOL; SALAZOSULFAPYRIDINE; SPARTEINE; SULFAMONOMETHOXINE; SULFANILAMIDE; SULFINPYRAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XANTHINE OXIDASE INHIBITOR; XENOBIOTIC AGENT; DRUG; ENZYME; OXIDOREDUCTASE;

BIOTRANSFORMATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG URINE LEVEL; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; ENZYME POLYMORPHISM; ETHNIC DIFFERENCE; FIRST PASS EFFECT; FLUSHING; FOOD DRUG INTERACTION; GENE DUPLICATION; GENE FREQUENCY; GENE MUTATION; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SEX DIFFERENCE; SPECIES DIFFERENCE; XENOBIOTIC METABOLISM; ANIMAL; CHEMISTRY; GENETICS; GENOTYPE; METABOLISM; MOUSE; MUTATION; PHARMACOKINETICS; RAT;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYMES; GENOTYPE; HUMANS; MICE; MUTATION; OXIDOREDUCTASES; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; POLYMORPHISM, GENETIC; RATS; SEX FACTORS; SPECIES SPECIFICITY;

EID: 59649101380     PISSN: 16121872     EISSN: 16121880     Source Type: Journal    
DOI: 10.1002/cbdv.200890214     Document Type: Review

References (333)

1. B. Testa, S. D. Krämer, 'The Biochemistry of Drug Metabolism - An Introduction. Part 1. Principles and Overview', Chem. Biodivers. 2006, 3, 1053-1101.
2. B. Testa, S. D. Krämer, 'The Biochemistry of Drug Metabolism - An Introduction. Part 2. Redox Reactions and Their Enzymes', Chem. Biodivers. 2007, 4, 257-405.
3. B. Testa, S. D. Krämer, 'The Biochemistry of Drug Metabolism - An Introduction. Part 3. Reactions of Hydrolysis and Their Enzymes', Chem. Biodivers. 2007, 4, 2031-2122.
4. B. Testa, S. D. Krämer, 'The Biochemistry of Drug Metabolism - An Introduction. Part 4. Conjugation Reactions and Their Enzymes', Chem. Biodivers. 2008, 5, 2171-2336.
5. M. Ingelman-Sundberg, C. Rodriguez-Antona, 'Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy', Philos. Trans. R. Soc. London, Ser. B: Biol. Sci. 2005, 360, 1563-1570.
6. M. Ingelman-Sundberg, S. C. Sim, A. Gomez, C. Rodriguez-Antona, 'Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects', Pharmacol. Ther. 2007, 116, 496-526.
7. B. Alberts, A. Johnson, J. Lewis, M. Raff, K. Roberts, P. Walter, 'Molecular Biology of the Cell', 5th edn., Garland Science, Oxford, 2007.
8. 'Molecular Biology WebBook' homepage, http://www.web-books.com/MoBio.
9. T. Strachan, A. P. Read, ' Human Molecular Genetics', 3rd edn., Garland Science, Oxford, 2003.
10. T. A. Brown, 'Genomes', 3rd edn., Garland Science, Oxford, 2006.
11. W. Kalow, U. A. Meyer, R. F. Tyndale, 'Pharmacogenomics', 2nd edn., Taylor & Francis, New York, 2005.
12. J. C. Lindon, E. Holmes, J. K. Nicholson, 'Metabonomics in pharmaceutical R&D', FEBS J. 2007, 274, 1140-1151.
13. 'Wikipedia' homepage, http://www.wikipedia.org.
14. N. Plant, 'Expressed sequence tags (ESTs) and single nucleotide polymorphisms (SNPs): What large-scale sequencing projects can tell us about ADME', Xenobiotica 2006, 36, 860-876.
15. D. R. Nelson, L. Koymans, T. Kamataki, J. J. Stegeman, R. Feyereisen, D. J. Waxman, M. R. Waterman, O. Gotoh, M. J. Coon, R. W. Estabrook, I. C. Gunsalus, D. W. Nebert, 'P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature', Pharmacogenetics 1996, 6, 1-42.
16. D. W. Nebert, M. Z. Dieter, 'The evolution of drug metabolism', Pharmacology 2000, 61, 124-135.
17. F. J. Gonzalez, D. W. Nebert, 'Evolution of the P450-gene superfamily - Animal plant warfare, molecular drive and human genetic-differences in drug oxidation', Trends Genet. 1990, 6, 182-186.
18. D. F. V. Lewis, E. Watson, B. G. Lake, 'Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics', Mutat. Res. 1998, 410, 245-270.
19. P. Ward, 'Oxygen - the breath of life', New Sci. 2007, April 27, 38-41.
20. V. Vasiliou, A. Bairoch, K. F. Tipton, D. W. Nebert, 'Eukaryotic aldehyde dehydrogenase (ALDH) genes: human polymorphisms, and recommended nomenclature based on divergent evolution and chromosomal mapping', Pharmacogenetics 1999, 9, 421-434.
21. M. Nei, N. Saitou, 'Genetic relationship of human populations and ethnic differences in reactions to drugs and food', in 'Ethnic Differences in Reactions to Drugs and Xenobiotics', Eds. W. Kalow, H. W. Goedde, D. P. Agarwal, Alan R. Liss, New York, 1986.
22. L. Bertilsson, 'Geographical interracial differences in polymorphic drug oxidation - Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19', Clin. Pharmacokinet. 1995, 29, 192-209.
23. M. W. Kirschner, J. C. Gerhart, 'The Plausibility of Life - Resolving Darwin's Dilemma', Yale University Press, New Haven, 2005.
24. T. R. E. Southwood, 'The Story of Life', Oxford University Press, Oxford, 2003.
25. B. S. Guttman, 'Evolution: A Beginner's Guide', Oneworld, Oxford, 2005.
26. R. Dawkins, 'The Ancestor's Tale, A Pilgrimage to the Dawn of Life', Weidenfeld & Nicolson, London, 2004.
27. 'NCBI: genome sequences' homepage, http://www.ncbi.nlm.nih.gov/Genomes/.
28. S. Lofgren, A. L. Hagbjork, S. Ekman, R. Fransson-Steen, Y. Terelius, 'Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison', Xenobiotica 2004, 34, 811-834.
29. 'Mouse Cytochrome P450s' homepage, http://drnelson.utmem.edu/ mouse.master.table.html.
30. 'Rat Cytochrome P450s' homepage, http://drnelson.utmem.edu/ rat.master.table.html.
31. 'Numbers of putatively functional full-length CYP genes in 54 whole eukaryotic genomes' homepage, http://drnelson.utmem.edu/Genome.list.htm.
32. 'ExPASy Proteomics Server' homepage, http://www.expasy.org.
33. M. Martignoni, G. M. M. Groothuis, R. de Kanter, 'Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction', Expert Opin. Drug Metab. Toxicol. 2006, 2, 875-894.
34. 'European Bioinformatics Institute' homepage, http://www.ebi.ac.uk/.
35. F. P. Guengerich, 'Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species', Chem.-Biol. Interact. 1997, 106, 161-182.
36. K. Kawajiri, J. Watanabe, S. I. Hayashi, 'Identification of allelic variants of the human CYP1A1 gene', Methods Enzymol. 1996, 272, 226-232.
37. K. Walton, J. L. C. M. Dorne, A. G. Renwick, 'Default factors for interspecies differences in the major routes of xenobiotic elimination', Hum. Ecol. Risk Assess. 2001, 7, 181-201.
38. C. A. Mugford, G. L. Kedderis, 'Sex-dependent metabolism of xenobiotics', Drug Metab. Rev. 1998, 30, 441-498.
39. F. P. Guengerich, 'Cytochrome P450s and other enzymes in drug metabolism and toxicity', AAPS J. 2006, 8, E101-E111.
40. M. Turpeinen, C. Ghiciuc, M. Opritoui, L. Tursas, O. Pelkonen, M. Pasanen, 'Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: a comparative study in vitro', Xenobiotica 2007, 37, 1367-1377.
41. D. V. Parke, 'Studies in detoxication. 84. The metabolism of [C-14]aniline in the rabbit and other animals', Biochem. J. 1960, 77, 493-503.
42. P. J. Creaven, D. V. Parke, R. T. Williams, 'A fluorimetric study of hydroxylation of biphenyl in vitro by liver preparations of various species', Biochem. J. 1965, 96, 879-885.
43. F. Berthou, B. Guillois, C. Riche, Y. Dreano, E. Jacqzaigrain, P. H. Beaune, 'Interspecies variations in caffeine metabolism related to cytochrome-P4501a enzymes', Xenobiotica 1992, 22, 671-680.
44. C. D. Davis, R. H. Adamson, E. G. Snyderwine, 'Studies on the mutagenic activation of heterocyclic amines by cynomolgus monkey, rat and human microsomes show that cynomolgus monkeys have a low capacity to N-oxidize the quinoxaline-type heterocyclic amines', Cancer Lett. 1993, 73, 95-104.
45. J. B. Keenaghan, R. N. Boyes, 'Tissue distribution, metabolism and excretion of lidocaine in rats, guinea-pigs, dogs and man', J. Pharmacol. Exp. Ther. 1972, 180, 459-463.
46. S. Imaoka, K. Enomoto, Y. Oda, A. Asada, M. Fujimori, T. Shimada, S. Fujita, F. P. Guengerich, Y. Funae, 'Lidocaine metabolism by human cytochrome-P-450s purified from hepatic microsomes - Comparison of those with rat hepatic cytochrome-P-450s', J. Pharmacol. Exp. Ther. 1990, 255, 1385-1391.
47. Y. Masubuchi, S. Umeda, S. Igarashi, S. Fujita, S. Narimatsu, T. Suzuki, 'Participation of the CYP2D subfamily in lidocaine 3-hydroxylation and formation of a reactive metabolite covalently bound to liver microsomal protein in rats', Biochem. Pharmacol. 1993, 46, 1867-1869.
48. B. G. Lake, 'Coumarin metabolism, toxicity and carcinogenicity: Relevance for human risk assessment', Food Chem. Toxicol. 1999, 37, 423-453.
49. D. F. V. Lewis, Y. Ito, B. G. Lake, 'Metabolism of coumarin by human P450s: A molecular modelling study', Toxicol. in Vitro 2006, 20, 256-264.
50. D. F. Lewis, B. G. Lake, 'Species differences in coumarin metabolism: a molecular modelling evaluation of CYP2A interactions', Xenobiotica 2002, 32, 547-561.
51. D. F. V. Lewis, B. G. Lake, 'Molecular modeling of members of the P4502a subfamily - Application to studies of enzyme specificity', Xenobiotica 1995, 25, 585-598.
52. S. L. Born, D. Caudill, K. L. Fliter, M. P. Purdon, 'Identification of the cytochromes P450 that catalyze coumarin 3,4-epoxidation and 3-hydroxylation', Drug Metab. Dispos. 2002, 30, 483-487.
53. M. J. Graham, A. R. Bell, H. K. Crewe, C. L. Moorcraft, L.Walker, E. F.Whittaker, M. S. Lennard, 'mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates', Xenobiotica 2003, 33, 225-237.
54. S. S. Shah, S. Sanda, N. L. Regmi, K. Sasaki, M. Shimoda, 'Characterization of cytochrome P450-mediated drug metabolism in cats', J. Vet. Pharmacol. Ther. 2007, 30, 422-428.
55. Y. Yoshigae, T. Imai, A. Horita, H. Matsukane, M. Otagiri, 'Species differences in stereoselective hydrolase activity in intestinal mucosa', Pharm. Res. 1998, 15, 626-631.
56. S. Kuribayashi, N. Ueda, S. Naito, H. Yamazaki, T. Kamataki, 'Species differences in hydrolase activities toward OT-7100 responsible for different bioavailability in rats, dogs, monkeys and humans', Xenobiotica 2006, 36, 301-314.
57. H. Wang, Z. Wang, S. Y. Wang, M. Li, L. Nan, J. K. Rhie, J. M. Covey, R.W. Zhang, D. L. Hill, 'Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent', Cancer Chemother. Pharmacol. 2005, 56, 255-260.
58. R. T. Williams, 'Comparative patterns of drug metabolism', Fed. Proc. 1967, 26, 1029-1039.
59. L. A. Trepanier, K. Ray, N. J. Winand, S. P. Spielberg, A. E. Cribb, 'Cytosolic arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes', Biochem. Pharmacol. 1997, 54, 73-80.
60. J. W. Bridges, M. R. Kibby, S. R. Walker, R. T. Williams, 'Structure and species as factors affecting metabolism of some methoxy-6-sulphanilamidopyrimidines', Biochem. J. 1969, 111, 167-172.
61. P. C. Hirom, R. L. Smith, R. T. Williams, P. Millburn, 'Species variations in threshold molecular-weight factor for biliary excretion of organic anions', Biochem. J. 1972, 129, 1071-1077.
62. M. M. Abou-El-Makarem, P. Millburn, R. L. Smith, R. T. Williams, 'Biliary excretion of foreign compounds - Species differences in biliary excretion', Biochem. J. 1967, 105, 1289-1293.
63. S. H. L. Chiu, S. E. W. Huskey, 'Species differences in N-glucuronidation', Drug Metab. Dispos. 1998, 26, 838-847.
64. S. C. Vashishtha, E. M. Hawes, D. J. McCann, O. Ghosheh, L. Hogg, 'Quaternary ammonium-linked glucuronidation of 1-substituted imidazoles by liver microsomes: Interspecies differences and structure-metabolism relationships', Drug Metab. Dispos. 2002, 30, 1070-1076.
65. T. Nakazawa, K. Miyata, K. Omura, T. Iwanaga, O. Nagata, 'Metabolic profile of FYX-051 (4-(5-pyridin-4-yl-1H-[1,2,4] triazol-3-yl)pyridine-2-carbonitrile) in the rat, dog, monkey, and human: Identification of N-glucuronides and N-glucosides', Drug Metab. Dispos. 2006, 34, 1880-1886.
66. K. Kassahun, E. Mattiuz, E. Nyhart, B. Obermeyer, T. Gillespie, A. Murphy, M. Goodwin, D. Tupper, J. T. Callaghan, L. Lemberger, 'Disposition and biotransformation of the antipsychotic agent olanzapine in humans', Drug Metab. Dispos. 1997, 25, 81-93.
67. O. Ghosheh, E. M. Hawes, 'Microsomal N-glucuronidation of nicotine and cotinine: Human hepatic interindividual, human intertissue, and interspecies hepatic variation', Drug Metab. Dispos. 2002, 30, 1478-1483.
68. X. H. Cao, S. T. Gibbs, L. Y. Fang, H. A. Miller, C. P. Landowski, H. C. Shin, H. Lennernas, Y. Q. Zhong, G. L. Amidon, L. X. Yu, D. X. Sun, 'Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model', Pharm. Res. 2006, 23, 1675-1686.
69. K. O'Brien, E. Moss, D. Judah, G. Neal, 'Metabolic basis of the species difference to aflatoxin B1 induced hepatotoxicity', Biochem. Biophys. Res. Commun. 1983, 114, 813-821.
70. J. J. Bogaards, M. Bertrand, P. Jackson, M. J. Oudshoorn, R. J. Weaver, P. J. van Bladeren, B. Walther, 'Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man', Xenobiotica 2000, 30, 1131-1152.
71. M. A. Shamat, 'The role of the gastrointestinal microflora in the metabolism of drugs', Int. J. Pharm. 1993, 97, 1-13.
72. H. A. Soleim, R. R. Scheline, 'Metabolism of xenobiotics by strains of intestinal bacteria', Acta Pharmacol. Toxicol. 1972, 31, 471-480.
73. M. Mikov, 'The metabolism of drugs by the gut flora', Eur. J. Drug Metab. Pharmacokinet. 1994, 19, 201-207.
74. C. Delomenie, S. Fouix, S. Longuemaux, N. Brahimi, C. Bizet, B. Picard, E. Denamur, J. M. Dupret, 'Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: Evidence for highly selective acetylation of 5-aminosalicylic acid', J. Bacteriol. 2001, 183, 3417-3427.
75. I. Singleton, 'Microbial metabolism of xenobiotics - Fundamental and applied research', J. Chem. Technol. Biotechnol. 1994, 59, 9-23.
76. H. P. Pan, J. R. Fouts, T. R. Devereux, ' Hepatic microsomal N-hydroxylation of para-chloroaniline and para-chloro-N-methylaniline in red-winged blackbird compared with rat', Xenobiotica 1979, 9, 441-446.
77. H. P. Pan, J. R. Fouts, 'Drug metabolism in birds', Pharmacology 1979, 19, 289-293.
78. K. Baert, S. Croubels, A. Maes, U. Hillaert, S. Van Calenbergh, P. De Backer, 'Comparative metabolic excretion profile of sodium salicylate in broiler chickens and homing pigeons', J. Vet. Pharmacol. Ther. 2004, 27, 123-127.
79. K. M. Kleinow, M. O. James, J. J. Lech, 'Drug pharmacokinetics and metabolism in food-producing fish and crustaceans - Methods and examples', ACS Symp. Ser. 1992, 503, 98-130.
80. D. Schlenk, 'Role of FMO in pesticide biotransformation in fish', Drug Metab. Rev. 2004, 36, 24-24.
81. M. Ingelman-Sundberg, M. Oscarson, A. K. Daly, S. Garte, D. W. Nebert, 'Human cytochrome P450 (CYP) genes: Aweb page for the nomenclature of alleles', Cancer Epidemiol. Biomarkers Prev. 2001, 10, 1307-1308.
82. M. Eichelbaum, 'Pharmacogenomics: towards individualized drug therapy', FEBS J. 2006, 273, 26-26.
83. M. Eichelbaum, M. Ingelman-Sundberg, W. E. Evans, 'Pharmacogenomics and individualized drug therapy', Annu. Rev. Med. 2006, 57, 119-137.
84. B. Chowbay, S. F. Zhou, E. J. D. Lee, 'An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: Experience in Singapore', Drug Metab. Rev. 2005, 37, 327-378.
85. L. H. Lash, R. N. Hines, F. J. Gonzalez, T. R. Zacharewski, M. A. Rothstein, 'Genetics and susceptibility to toxic chemicals: Do you (or should you) know your genetic profile?', J. Pharmacol. Exp. Ther. 2003, 305, 403-409.
86. U. A. Meyer, U. M. Zanger, 'Molecular mechanisms of genetic polymorphisms of drug metabolism', Annu. Rev. Pharmacol. Toxicol. 1997, 37, 269-296.
87. W. E. Evans, M. V. Relling, 'Pharmacogenomics: Translating functional genomics into rational therapeutics', Science 1999, 286, 487-491.
88. L. L. Cavalli-Sforza, P. Manozzi, A. Piazza, 'The History and Geography of Human Genes', Princeton University Press, Princeton, NJ, 1994.
89. A. Manica, W. Amos, F. Balloux, T. Hanihara, 'The effect of ancient population bottlenecks on human phenotypic variation', Nature 2007, 448, 346-U346.
90. N. A. Rosenberg, J. K. Pritchard, J. L. Weber, H. M. Cann, K. K. Kidd, L. A. Zhivotovsky, M. W. Feldman, 'Genetic structure of human populations', Science 2002, 298, 2381-2385.
91. E. Trinkaus, 'Early modern humans', Annu. Rev. Anthropol. 2005, 34, 207-230.
92. Q. Ayub, A. Mansoor, M. Ismail, S. Khaliq, A. Mohyuddin, A. Hameed, K. Mazhar, S. Rehman, S. Siddiqi, M. Papaioannou, A. Piazza, L. L. Cavalli-Sforza, S. Q. Mehdi, 'Reconstruction of human evolutionary tree using polymorphic autosomal microsatellites', Am. J. Phys. Anthropol. 2003, 122, 259-268.
93. D. Jones, 'Going global', New Sci. 2007, October 27, 36-41.
94. J. D. Hawks, M. H. Wolpoff, 'The four faces of Eve: hypothesis compatibility and human origins', Quatern. Int. 2001, 75, 41-50.
95. K. W. Bock, D. Schrenk, A. Forster, E. U. Griese, K. Morike, D. Brockmeier, M. Eichelbaum, 'The influence of environmental and genetic factors on CYP2D6, CYP1A2, and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes', Pharmacogenetics 1994, 4, 209-218.
96. T. M. Bosch, I. Meijerman, J. H. Beijnen, J. H. M. Schellens, 'Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer', Clin. Pharmacokinet. 2006, 45, 253-285.
97. D. F. Lewis, C. Ioannides, D. V. Parke, 'Cytochromes P450 and species differences in xenobiotic metabolism and activation of carcinogen', Environ. Health Perspect. 1998, 106, 633-641.
98. D. W. J. Clark, 'Genetically determined variability in acetylation and oxidation - Therapeutic implications', Drugs 1985, 29, 342-375.
99. N. Jourenkova-Mironova, H. Wikman, C. Bouchardy, K. Mitrunen, P. Dayer, S. Benhamou, A. Hirvonen, 'Role of arylamine N-acetyltransferase 1 and 2 (NAT1 and NAT2) genotypes in susceptibility to oral/pharyngeal and laryngeal cancers', Pharmacogenetics 1999, 9, 533-537.
100. C. Rodriguez-Antona, M. Ingelman-Sundberg, 'Cytochrome P450 pharmacogenetics and cancer', Oncogene 2006, 25, 1679-1691.
101. D. M. Grant, N. C. Hughes, S. A. Janezic, G. H. Goodfellow, H. J. Chen, A. Gaedigk, V. L. Yu, R. Grewal, 'Human acetyltransferase polymorphisms', Mutat. Res. 1997, 376, 61-70.
102. R. M. Weinshilboum, D. M. Otterness, C. L. Szumlanski, 'Methylation pharmacogenetics: Catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase', Annu. Rev. Pharmacol. Toxicol. 1999, 39, 19-52.
103. T. R. Rebbeck, J. M. Jaffe, A. H. Walker, A. J. Wein, S. B. Malkowicz, 'Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4', J. Natl. Cancer Inst. 1998, 90, 1225-1229.
104. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, F. P. Guengerich, 'Interindividual variations in human liver cytochrome-P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals - Studies with liver microsomes of 30 Japanese and 30 Caucasians', J. Pharmacol. Exp. Ther. 1994, 270, 414-423.
105. T. Mizutani, 'PM frequencies of major CYPs in Asians and Caucasians', Drug Metab. Rev. 2003, 35, 99-106.
106. R. J. Weaver, 'Assessment of drug-drug interactions concepts and approaches', Xenobiotica 2001, 31, 499-538.
107. S. Rendic, F. J. DiCarlo, 'Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors', Drug Metab. Rev. 1997, 29, 413-580.
108. S. Rendic, F. P. Guengerich, 'Special issue on human cytochromes P450 (human CYPs): Human cytochrome P450 enzymes, a status report summarizing their reactions, substrates, inducers, and inhibitors - 1st update - Foreword', Drug Metab. Rev. 2002, 34, IX-X.
109. U. M. Zanger, K. Klein, T. Saussele, J. Blievernicht, M. H. Hofmann, M. Schwab, 'Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance', Pharmacogenomics 2007, 8, 743-759.
110. M. Ingelman-Sundberg, 'Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity', Pharmacogenomics J. 2005, 5, 6-13.
111. C. Rodriguez-Antona, J. G. Sayi, L. L. Gustafsson, L. Bertilsson, M. Ingelman-Sundberg, 'Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles', Biochem. Biophys. Res. Commun. 2005, 338, 299-305.
112. 'PharmacoGenetics for Every Nation Initiative (PGENI)' homepage, http://pgeni.unc.edu/.
113. S. Rendic, 'Summary of information on human CYP enzymes: Human P450 metabolism data', Drug Metab. Rev. 2002, 34, 83-448.
114. D.W. Nebert, 'Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology', Pharmacogenetics 2000, 10, 279-290.
115. M. Ingelman-Sundberg, A. K. Daly, M. Oscarson, D. W. Nebert, 'Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles', Pharmacogenetics 2000, 10, 91-93.
116. K. Ikeya, A. K. Jaiswal, R. A. Owens, J. E. Jones, D. W. Nebert, S. Kimura, ' Human CYP1A2 - sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 messenger-RNA expression', Mol. Endocrinol. 1989, 3, 1399-1408.
117. M. Murray, 'Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents', J. Pharm. Pharmacol. 2006, 58, 871-885.
118. H. J. Zhou, P. D. Josephy, D. Kim, F. P. Guengerich, 'Functional characterization of four allelic variants of human cytochrome P450 1A2', Arch. Biochem. Biophys. 2004, 422, 23-30.
119. C. Sachse, J. Brochmoller, S. Bauer, I. Roots, 'Functional significance of a C> A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine', Br. J. Clin. Pharmacol. 1999, 47, 445-449.
120. R. Ghotbi, M. Christensen, H. K. Roh, M. Ingelman-Sundberg, E. Aklillu, L. Bertilsson, 'Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans', Eur. J. Clin. Pharmacol. 2007, 63, 537-546.
121. 'Human Cytochrome P450 (CYP) Allele Nomenclature Committee' homepage, http://www.cypalleles.ki.se.
122. J. C. Mwenifumbo, R. F. Tyndale, 'Genetic variability in CYP2A6 and the pharmacokinetics of nicotine', Pharmacogenomics 2007, 8, 1385-1402.
123. M. Oscarson, 'Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: Implications for interindividual differences in nicotine metabolism', Drug Metab. Dispos. 2001, 29, 91-95.
124. P. Fernandez-Salguero, S. M. G. Hoffman, S. Cholerton, H. Mohrenweiser, H. Raunio, A. Rautio, O. Pelkonen, J. D. Huang, W. E. Evans, J. R. Idle, F. J. Gonzalez, 'A genetic-polymorphism in coumarin 7-hydroxylation - sequence of the human Cyp2a genes and identification of variant Cyp2a6 alleles', Am. J. Hum. Genet. 1995, 57, 651-660.
125. M. Nakajima, 'Smoking behavior and related cancers: The role of CYP2A6 polymorphisms', Curr. Opin. Mol. Ther. 2007, 9, 538-544.
126. Y. S. Rao, E. Hoffmann, M. Zia, L. Bodin, M. Zeman, E. M. Sellers, R. F. Tyndale, 'Duplications and defects in the CYP2A6 gene: Identification, genotyping, and in vivo effects on smoking', Mol. Pharmacol. 2000, 58, 747-755.
127. N. Ariyoshi, H. Sekine, K. Nakayama, K. Saito, A. Miyamoto, T. Kamataki, 'Identification of deletion-junction site of CYP2A6*4B allele lacking entire coding region of CYP2A6 in Japanesed', Pharmacogenetics 2004, 14, 701-705.
128. M. Nakajima, J. T. Kwon, N. Tanaka, T. Zenta, Y. Yamamoto, H. Yamamoto, H. Yamazaki, T. Yamamoto, Y. Kuroiwa, T. Yokoi, 'Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans', Clin. Pharmacol. Ther. 2001, 69, 72-78.
129. M. L. Pianezza, E. M. Sellers, R. F. Tyndale, 'Genetically variable CYP2A6 influences smoking behaviour', Clin. Pharmacol. Ther. 1998, 63, 171-171.
130. H. Z. Ring, A. M. Valdes, D. M. Nishita, S. Prasad, P. Jacob, 3rd, R. F. Tyndale, G. E. Swan, N. L. Benowitz, 'Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism', Pharmacogenet. Genomics 2007, 17, 1007-1015.
131. A. Rossini, D. C. Rapozo, S. C. Soares Lima, D. P. Guimaraes, M. A. Ferreira, R. Teixeira, C. D. Kruel, S. G. Barros, N. A. Andreollo, R. Acatauassu, H. J. Matos, R. M. Albano, L. F. Pinto, 'Polymorphisms of GSTP1 and GSTT1, but not of CYP2A6, CYP2E1 or GSTM1, modify the risk for esophageal cancer in a western population', Carcinogenesis 2007, 28, 2537-2542.
132. N. Farinola, N. B. Piller, 'CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients?', Pharmacogenomics 2007, 8, 151-158.
133. K. Klein, T. Lang, T. Saussele, E. Barbosa-Sicard, W. H. Schunck, M. Eichelbaum, M. Schwab, M. Schwab, U. M. Zanger, 'Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz', Pharmacogenet. Genomics 2005, 15, 861-873.
134. V. Lamba, J. Lamba, K. Yasuda, S. Strom, J. Davila, M. L. Hancock, J. D. Fackenthal, P. K. Rogan, B. Ring, S. A. Wrighton, E. G. Schuetz, 'Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression', J. Pharmacol. Exp. Ther. 2003, 307, 906-922.
135. J. Kirchheiner, C. Klein, I. Meineke, J. Sasse, U. M. Zanger, T. E. Murdter, I. Roots, J. Brockmoller, 'Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6', Pharmacogenetics 2003, 13, 619-626.
136. K. Tsuchiya, H. Gatanaga, N. Tachikawa, K. Teruya, Y. Kikuchi, M. Yoshino, T. Kuwahara, T. Shirasaka, S. Kimura, S. Oka, 'Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens', Biochem. Biophys. Res. Commun. 2004, 319, 1322-1326.
137. J. Zukunft, T. Lang, T. Richter, K. I. Hirsch-Ernst, A. K. Nussler, K. Klein, M. Schwab, M. Eichelbaum, U. M. Zanger, 'A natural CYP2B6 TATA box polymorphism (- 82T → C) leading to enhanced transcription and relocation of the transcriptional start sited', Mol. Pharmacol. 2005, 67, 1772-1782.
138. J. P. Gill, E. G. Berglund, 'CYP2C8 and antimalaria drug efficacy', Pharmacogenomics 2007, 8, 187-198.
139. J. Kirchheiner, J. Brockmoller, 'Clinical consequences of cytochrome P450 2C9 polymorphisms', Clin. Pharmacol. Ther. 2005, 77, 1-16.
140. J. A. Goldstein, 'Clinical relevance of genetic polymorphisms in the human CYP2C subfamily', Br. J. Clin. Pharmacol. 2001, 52, 349-355.
141. W. Xie, R. M. Evans, 'Orphan nuclear receptors: The exotics of xenobiotics', J. Biol. Chem. 2001, 276, 37739-37742.
142. S. C. Sim, C. Risinger, M. L. Dahl, E. Aklillu, M. Christensen, L. Bertilsson, M. Ingelman-Sundberg, 'A common novel CTP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants', Clin. Pharmacol. Ther. 2006, 79, 103-113.
143. L. Bertilsson, M. L. Dahl, 'Polymorphic drug oxidation - Relevance to the treatment of psychiatric disorders', CNS Drugs 1996, 5, 200-223.
144. A. Kaneko, J. K. Lum, J. Yaviong, N. Takahashi, T. Ishizaki, L. Bertilsson, T. Kobayakawa, A. Bjorkman, 'High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands', Pharmacogenetics 1999, 9, 581-590.
145. J. Kirchheiner, K. Nickchen, M. Bauer, M. L. Wong, J. Licinio, I. Roots, J. Brockmoller, 'Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response', Mol. Psychiatry 2004, 9, 442-473.
146. N. Murayama, N. Imai, T. Nakane, M. Shimizu, H. Yamazaki, 'Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes', Biochem. Pharmacol. 2007, 73, 2020-2026.
147. W. Hammer, F. Sjoqvist, 'Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds', Life Sci. 1967, 6, 1895-1903.
148. A. Mahgoub, J. R. Idle, L. G. Dring, R. Lancaster, R. L. Smith, 'Population and familial study of defective hydroxylation of debrisoquine', Br. J. Clin. Pharmacol. 1977, 4, P726-P726.
149. A. Mahgoub, J. R. Idle, L. G. Dring, R. Lancaster, R. L. Smith, 'Polymorphic hydroxylation of debrisoquine in man', Lancet 1977, 2, 584-586.
150. G. T. Tucker, J. H. Silas, A. O. Iyun, M. S. Lennard, A. J. Smith, 'Polymorphic hydroxylation of debrisoquine', Lancet 1977, 2, 718-718.
151. M. Eichelbaum, N. Spannbrucker, H. J. Dengler, 'Influence of the defective metabolism of sparteine on its pharmacokinetics', Eur. J. Clin. Pharmacol. 1979, 16, 189-194.
152. M. Eichelbaum, N. Spannbrucker, B. Steincke, H. J. Dengler, 'Defective N-oxidation of sparteine in man - New pharmacogenetic defect', Eur. J. Clin. Pharmacol. 1979, 16, 183-187.
153. U. M. Zanger, S. Raimundo, M. Eichelbaum, 'Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry', Naunyn-Schmiedebergb's Arch. Pharmacol. 2004, 369, 23-37.
154. J. Sistonen, A. Sajantila, O. Lao, J. Corander, G. Barbujani, S. Fuselli, 'CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structured', Pharmacogenet. Genomics 2007, 17, 93-101.
155. L. D. Bradford, 'CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants', Pharmacogenomics 2002, 3, 229-243.
156. A. Gaedigk, L. D. Bradford, K. A. Marcucci, J. S. Leeder, 'Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans', Clin. Pharmacol. Ther. 2002, 72, 76-89.
157. D. Marez, M. Legrand, N. Sabbagh, J. M. LoGuidice, C. Spire, J. J. Lafitte, U. A. Meyer, F. Broly, 'Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution', Pharmacogenetics 1997, 7, 193-202.
158. R. A. McLellan, M. Oscarson, J. Seidegard, D. A. P. Evans, M. Ingelman-Sundberg, 'Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians', Pharmacogenetics 1997, 7, 187-191.
159. M. F. Fromm, H. K. Kroemer, M. Eichelbaum, 'Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs', Adv. Drug Delivery Rev. 1997, 27, 171-199.
160. E. Aklillu, I. Persson, L. Bertilsson, I. Johansson, F. Rodrigues, M. Ingelman-Sundberg, 'Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles', J. Pharmacol. Exp. Ther. 1996, 278, 441-446.
161. S. Raimundo, R. Fischer, M. Eichelbaum, E. U. Griese, M. Schwab, U. M. Zanger, 'Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6', Pharmacogenetics 2000, 10, 577-581.
162. U. M. Zanger, J. Fischer, S. Raimundo, T. Stuven, B. O. Evert, M. Schwab, M. Eichelbaum, 'Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6', Pharmacogenetics 2001, 11, 573-585.
163. W. M. Cai, D. M. Nikoloff, R. M. Pan, J. de Leon, P. Fanti, M. Fairchild, W. H. Koch, P. J. Wedlund, 'CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing', Pharmacogenomics J. 2006, 6, 343-350.
164. M. Ueda,G. Hirokane, S. Morita, M. Okawa, T. Watanabe, K. Akiyama, K. Shimoda, 'The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients', Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30, 486-491.
165. Y. Ikenaga, T. Fukuda, K. Fukuda, Y. Nishida, M. Naohara, H. Maune, J. Azuma, 'The frequency of candidate alleles for CYP2D6 genotyping in the Japanese population with an additional respect to the - 1584C to G substitution', Drug Metab. Pharmacokinet. 2005, 20, 113-116.
166. A. Gaedigk, L. D. Bradford, S. W. Alander, J. S. Leeder, 'CYP2D6*36 gene arrangements within the CYP2D6 locus: Association of CYP2D6*36 with poor metabolizer status', Drug Metab. Dispos. 2006, 34, 563-569.
167. I. Cascorbi, 'Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication', Eur. J. Clin. Invest. 2003, 33, 17-22.
168. D. M. Roden, A. L. George, 'The genetic basis of variability in drug responses', Nat. Rev. Drug Discovery 2002, 1, 37-44.
169. R. R. Shah, 'Implications of pharmacogenetics for the regulatory assessment of new chemical entities', Pharm. News 2000, 7, 32-38.
170. H. Carmo, M. Brulport, M. Hermes, F. Oesch, D. de Boer, F. Remiao, F. Carvalho, M. R. Schon, N. Krebsfaenger, J. Doehmer, M. D. Bastos, J. G. Hengstler, 'CYP2D6 increases toxicity of the designer drug 4-methylthioamphetamine (4-MTA)', Toxicology 2007, 229, 236-244.
171. M. Eichelbaum, K. P. Reetz, E. K. Schmidt, C. Zekorn, 'The genetic polymorphism of sparteine metabolism', Xenobiotica 1986, 16, 465-481.
172. G. Mikus, A. S. Gross, J. Beckmann, R. Hertrampf, U. Gundert-Remy, M. Eichelbaum, 'The Influence of the sparteine debrisoquin phenotype on the disposition of flecainide', Clin. Pharmacol. Ther. 1989, 45, 562-567.
173. J. Turgeon, C. Fiset, R. Giguere, M. Gilbert, K. Moerike, J. R. Rouleau, H. K. Kroemer, M. Eichelbaum, O. Grechbelanger, P. M. Bélanger, 'Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man', J. Pharmacol. Exp. Ther. 1991, 259, 789-798.
174. C. Zekorn, G. Achtert, H. J. Hausleiter, C. H. Moon, M. Eichelbaum, 'Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation', Klin. Wochenschr. 1985, 63, 1180-1186.
175. P. Langguth, G. Fricker, H. Wunderli-Allenspach, 'Biopharmazied', Wiley-VCH, Weinheim, 2004.
176. M. Rowland, T. N. Tozer, 'Clinical Pharmacokinetics: Concepts and Applications', 3rd edn., Lippincott Williams & Wilkins, Philadelphia, 1995.
177. M. P. Goetz, J. M. Rae, V. J. Suman, S. L. Safgren, M. M. Ames, D. W. Visscher, C. Reynolds, F. J. Couch, W. L. Lingle, D. A. Flockhart, Z. Desta, E. A. Perez, J. N. Ingle, 'Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes', J. Clin. Oncol. 2005, 23, 9312-9318.
178. M. P. Goetz, A. Kamal, M. M. Ames, 'Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response', Clin. Pharmacol. Ther. 2008, 83, 160-166.
179. J. H. M. Schellens, P. A. Soons, D. D. Breimer, 'Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects', Biochem. Pharmacol. 1988, 37, 2507-2510.
180. V. Ozdemir, W. Kalow, B. K. Tang, A. D. Paterson, S. E. Walker, L. Endrenyi, A. D. M. Kashuba, 'Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method', Pharmacogenetics 2000, 10, 373-388.
181. J. K. Lamba, Y. S. Lin, E. G. Schuetz, K. E. Thummel, 'Genetic contribution to variable human CYP3A-mediated metabolism', Adv. Drug Delivery Rev. 2002, 54, 1271-1294.
182. H. G. Xie, A. J. J. Wood, R. B. Kim, C. M. Stein, G. R. Wilkinson, 'Genetic variability in CYP3A5 and its possible consequences', Pharmacogenomics 2004, 5, 243-272.
183. J. C. Gorski, S. D. Hall, M. Vandenbranden, S. A. Wrighton, D. R. Jones, 'Regioselective biotransformation of midazolam by members of the human cytochrome-P450-3A (CYP3A) subfamily', Biochem. Pharmacol. 1994, 47, 1643-1653.
184. T. Kronbach, D. Mathys, M. Umeno, F. J. Gonzalez, U. A. Meyer, 'Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4', Mol. Pharmacol. 1989, 36, 89-96.
185. J. Y. Park, K. A. Kim, P. L. Park, O. J. Lee, D. K. Kang, J. H. Shon, K. H. Liu, J. G. Shin, 'Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects', Clin. Pharmacol. Ther. 2006, 79, 590-599.
186. Y. Dai, M. F. Hebert, N. Isoherranen, C. L. Davis, C. Marsh, D. D. Shen, K. E. Thummel, 'Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro', Drug Metab. Dispos. 2006, 34, 836-847.
187. D. A. Hesselink, R. H. N. van Schaik, I. P. van der Heiden, M. van der Werf, P. J. H. S. Gregoor, J. Lindemans, W. Weimar, T. van Gelder, 'Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus', Clin. Pharmacol. Ther. 2003, 74, 245-254.
188. K. A. Kim, P. W. Park, O. J. Lee, D. K. Kang, J. Y. Park, 'Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects', J. Clin. Pharmacol. 2007, 47, 87-93.
189. P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem, J. Schuetz, P. B. Watkins, A. Daly, S. A. Wrighton, S. D. Hall, P. Maurel, M. Relling, C. Brimer, K. Yasuda, R. Venkataramanan, S. Strom, K. Thummel, M. S. Boguski, E. Schuetz, 'Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression', Nat. Genet. 2001, 27, 383-391.
190. C. T. Dolphin, T. E. Cullingford, E. A. Shephard, R. L. Smith, I. R. Phillips, 'Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FMO1, FM03 and FM04', Eur. J. Biochem. 1996, 235, 683-689.
191. S. B. Koukouritaki, R. N. Hines, 'Flavin-containing monooxygenase genetic polymorphism: impact on chemical metabolism and drug development', Pharmacogenomics 2005, 6, 807-822.
192. B. Furnes, D. Schlenk, 'Evaluation of xenobiotic N- and S-oxidation by variant flavin-containing monooxygenase 1 (FMO1) enzymes', Toxicol. Sci. 2004, 78, 196-203.
193. R. N. Hines, Z. H. Luo, K. A. Hopp, E. T. Cabacungan, S. B. Koukouritaki, D. G. McCarver, 'Genetic variability at the human FMO1 locus: Significance of a basal promoter Yin Yang 1 element polymorphism (FMO1*6)', J. Pharmacol. Exp. Ther. 2003, 306, 1210-1218.
194. S. B. Koukouritaki,M. T. Poch, M. C. Henderson, L. K. Siddens, S. K. Krueger, J. E. VanDyke, D. E. Williams, N. M. Pajewski, T. Wang, R. N. Hines, 'Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants', J. Pharmacol. Exp. Ther. 2007, 320, 266-273.
195. C. K. Yeung, E. T. Adman, A. E. Rettie, 'Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria', Arch. Biochem. Biophys. 2007, 464, 251-259.
196. H. Yamazaki, M. Shimizu, 'Genetic polymorphism of the flavin-containing monooxygenase 3 (FMO3) associated with trimethylaminuria (fish odor syndrome): Observations from Japanese patients', Curr. Drug Metab. 2007, 8, 487-491.
197. M. Shimizu, H. Yano, S. Nagashima, N. Murayama, J. Zhang, J. R. Cashman, H. Yamazaki, 'Effect of genetic variants of the human flavin-containing monooxygenase 3 on N- and S-oxygenation activities', Drug Metab. Dispos. 2007, 35, 328-330.
198. W. G. Chung, C. S. Park, H. K. Roh, W. K. Lee, Y. N. Cha, 'Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450', Jpn. J. Pharmacol. 2000, 84, 213-220.
199. J. R. Cashman, J. Zhang, 'Human flavin-containing monooxygenases', Annu. Rev. Pharmacol. Toxicol. 2006, 46, 65-100.
200. I. M. Hisamuddin, V. W. Yang, 'Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives', Pharmacogenomics 2007, 8, 635-643.
201. J. Zhou, E. A. Shephard, 'Mutation, polymorphism and perspectives for the future of human flavin-containing monooxygenase 3', Mutat. Res. 2006, 612, 165-171.
202. D. Hao, J. Sun, B. Furnes, D. Schlenk, M. Li, S. Yang, L. Yang, 'Allele and genotype frequencies of polymorphic FMO3 gene in two genetically distinct populations', Cell Biochem. Funct. 2007, 25, 443-453.
203. 'Database for allelic variants of FMO3' homepage, http://human-fmo3.biochem.ucl.ac.uk/Human_-FMO3/.
204. C. Sachse, S. Ruschen, M. Dettling, J. Schley, S. Bauer, B. Muller-Oerlinghausen, I. Roots, J. Brockmoller, 'Flavin monooxygenase 3 (FMO3) polymorphism in a white population: Allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism', Clin. Pharmacol. Ther. 1999, 66, 431-438.
205. S. B. Koukouritaki,M. T. Poch, E. T. Cabacungan, D. G. McCarver, R. N. Hines, 'Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants', Mol. Pharmacol. 2005, 68, 383-392.
206. H. J. Edenberg, 'The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants', Alcohol Res. Health 2007, 30, 5-13.
207. G. M. Pastino, E. J. Flynn, L. G. Sultatos, 'Genetic polymorphisms in ethanol metabolism: Issues and goals for physiologically based pharmacokinetic modeling', Drug Chem. Toxicol. 2000, 23, 179-201.
208. M. V. Osier, A. J. Pakstis, H. Soodyall, D. Comas, D. Goldman, A. Odunsi, F. Okonofua, J. Parnas, L. O. Schulz, J. Bertranpetit, B. Bonne-Tamir, R. B. Lu, J. R. Kidd, K. K. Kidd, 'A global perspective on genetic variation at the ADH genes reveals unusual patterns of linkage disequilibrium and diversity', Am. J. Hum. Genet. 2002, 71, 84-99.
209. H. W. Goedde, D. P. Agarwal, G. Fritze, D. Meiertackmann, S. Singh, G. Beckmann, K. Bhatia, L. Z. Chen, B. Fang, R. Lisker, Y. K. Paik, F. Rothhammer, N. Saha, B. Segal, L. M. Srivastava, A. Czeizel, 'Distribution of ADH2 and ALDH2 genotypes in different populations', Hum. Genet. 1992, 88, 344-346.
210. W. F. Bosron, T. K. Li, 'Genetic polymorphism of human liver alcohol and aldehyde dehydrogenases, and their relationship to alcohol metabolism and alcoholism', Hepatology 1986, 6, 502-510.
211. K. Matsuo, A. Hiraki, K. Hirose, H. Ito, T. Suzuki, K. Wakai, K. Tajima, 'Impact of the alcohol dehydrogenase (ADH) 1C and ADH1B polymorphisms on drinking behavior in nonalcoholic Japanese', Hum. Mutat. 2007, 28, 506-510.
212. Y. D. Neumark, Y. Friedlander, R. Durst, E. Leitersdorf, D. Jaffe, V. A. Ramchandani, S. O'Connor, L. G. Carr, T. K. Li, 'Alcohol dehydrogenase polymorphisms influence alcohol elimination rates in a male Jewish population', Alcohol Clin. Exp. Res. 2004, 28, 10-14.
213. H. K. Seitz, P. Becker, 'Alcohol metabolism and cancer risk', Alcohol Res. Health 2007, 30, 38-41, 44-37.
214. R. S. Wang, T. Nakajima, T. Kawamoto, T. Honma, 'Effects of aldehyde dehydrogenase-2 genetic polymorphisms on metabolism of structurally different aldehydes in human liver', Drug Metab. Dispos. 2002, 30, 69-73.
215. 'Human Polymorphisms of ALDH Genes' homepage, http://www.uchsc.edu/sop/ pharmscience/-alcdbase/hpol-aldh.html.
216. S. Singh, G. Fritze, B. Fang, S. Harada, Y. K. Paik, R. Eckey, D. P. Agarwal, H.W. Goedde, 'Inheritance of mitochondrial aldehyde dehydrogenase - Genotyping in Chinese, Japanese and South Korean families reveals dominance of the mutant allele', Hum. Genet. 1989, 83, 119-121.
217. G. K. Chambers, S. J. Marshall, G. M. Robinson, S. Maguire, J. Newton-Howes, N. L. Chong, 'The genetics of alcoholism in Polynesians: Alcohol and aldehyde dehydrogenase genotypes in young men', Alcohol Clin. Exp. Res. 2002, 26, 949-955.
218. T. Matsuda, H. Yabushita, R. A. Kanaly, S. Shibutani, A. Yokoyama, 'Increased DNA damage in ALDH2-deficient alcoholics', Chem. Res. Toxicol. 2006, 19, 1374-1378.
219. J. Abraham, H. M. Earl, P. D. Pharoah, C. Caldas, 'Pharmacogenetics of cancer chemotherapy', Biochim. Biophys. Acta 2006, 1766, 168-183.
220. T. Hasegawa, H. B. Kim, M. Fukushima, Y. Wataya, 'Sequence analysis of the 5′-flanking regions of human dihydropyrimidine dehydrogenase gene: Identification of a new polymorphism related with effects of 5-fluorouracil', Nucleosides Nucleotides Nucleic Acids 2005, 24, 233-242.
221. K. Maekawa, M. Saeki, Y. Saito, S. Ozawa, K. Kurose, N. Kaniwa, M. Kawamoto, N. Kamatani, K. Kato, T. Hamaguchi, Y. Yamada, K. Shirao, Y. Shimada, M. Muto, T. Doi, A. Ohtsu, T. Yoshida, Y. Matsumura, N. Saijo, J. Sawada, 'Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences', J. Hum. Genet. 2007, 52, 804-819.
222. J. G. Maring, H. J. M. Groen, F. M. Wachters, D. R. A. Uges, E. G. E. de Vries, 'Genetic factors influencing pyrimidine-antagonist chemotherapy', Pharmacogenomics J. 2005, 5, 226-243.
223. W. P. Yong, F. Innocenti, M. J. Ratain, 'The role of pharmacogenetics in cancer therapeutics', Br. J. Clin. Pharmacol. 2006, 62, 35-46.
224. M. C. McGuire, C. P. Nogueira, C. F. Bartels, H. Lightstone, A. Hajra, A. F. L. Van der Spek, O. Lockridge, B. N. La Du, 'Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase', Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 953-957.
225. G. Lando, A. Mosca, R. Bonora, F. Azzario, S. Penco, A. Marocchi, M. Panteghini, M. C. Patrossoa, 'Frequency of butyrylcholinesterase gene mutations in individuals with abnormal inhibition numbers: an Italian population study', Pharmacogenetics 2003, 13, 265-270.
226. F. S. Jensen, J. Viby-Mogensen, 'Plasma cholinesterase and abnormal reaction to succinylcholine - 20 years experience with the Danish-Cholinesterase-Research-Unit', Acta Anaesthesiol. Scand. 1995, 39, 150-156.
227. G. Pestel, H. Sprenger, A. Rothhammer, 'Frequency distribution of dibucaine numbers in 24,830 patients', Anaesthesist 2003, 52, 495-499.
228. D. Ostergaard, J. Viby-Mogensen, S. N. Rasmussen, M. R. Gatke, F. Varin, 'Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically homozygous for the atypical plasma cholinesterase variant - Effect of injection of human cholinesterase', Anesthesiology 2005, 102, 1124-1132.
229. C. F. Bartels, F. S. Jensen, O. Lockridge, A. F. L. Vanderspek, H. M. Rubinstein, T. Lubrano, B. N. Ladu, 'DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites', Am. J. Hum. Genet. 1992, 50, 1086-1103.
230. C. Barta, M. Sasvari-Szekely, A. Devai, E. Kovacs, M. Staub, P. Enyedi, 'Analysis of mutations in the plasma cholinesterase gene of patients with a history of prolonged neuromuscular block during anesthesia', Mol. Genet. Metab. 2001, 74, 484-488.
231. 'Cholinesterase', Ed. M. Whittaker, Karger, Basel, 1986.
232. C. E. Furlong, 'Genetic variability in the cytochrome P450-paraoxonase 1 (PON1) pathway for detoxication of organophosphorus compounds', J. Biochem. Mol. Toxicol. 2007, 21, 197-205.
233. E. Mutch, A. K. Daly, F. M. Williams, 'The relationship between PON1 phenotype and PON1-192 genotype in detoxification of three oxons by human liver', Drug Metab. Dispos. 2007, 35, 315-320.
234. N. Ferre, J. Camps, J. Fernandez-Ballart, V. Arija, M. M. Murphy, S. Ceruelo, E. Biarnes, E. Vilella, M. Tous, J. Joven, ' Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population', Clin. Chem. 2003, 49, 1491-1497.
235. W. F. Li, L. G. Costa, R. J. Richter, T. Hagen, D. M. Shih, A. Tward, A. J. Lusis, C. E. Furlong, 'Catalytic efficiency determines the in vivo efficacy of PON1 for detoxifying organophosphorus compounds', Pharmacogenetics 2000, 10, 767-779.
236. K. A. O'Leary, R. J. Edwards, M. M. Town, A. R. Boobis, 'Genetic and other sources of variation in the activity of serum paraoxonase/ diazoxonase in humans: consequences for risk from exposure to diazinon', Pharmacogenet. Genomics 2005, 15, 51-60.
237. D. K. Sanghera, S. Manzi, R. L. Minster, P. Shaw, A. Kao, F. Bontempo, M. I. Kamboh, 'Genetic variation in the paraoxonase-3 (PON3) gene is associated with serum PON1 activity', Ann. Hum. Genet. 2008, 72, 72-81.
238. J. Chen, W. Chan, S. Wallenstein, G. Berkowitz, J. G. Wetmur, 'Haplotype-phenotype relationships of paraoxonase-1', Cancer Epidemiol. Biomarkers Prev. 2005, 14, 731-734.
239. L. G. Costa, T. B. Cole, G. P. Jarvik, C. E. Furlong, 'Functional genomics of the paraoxonase (PON1) polymorphisms: Effects on pesticide sensitivity, cardiovascular disease, and drug metabolism', Annu. Rev. Med. 2003, 54, 371-392.
240. M. A. Palmatier, A. M. Kang, K. K. Kidd, 'Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles', Biol. Psychiatry 1999, 46, 557-567.
241. A. J. Shield, B. A. Thomae, B.W. Eckloff, E. D. Wieben, R. M. Weinshilboum, 'Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes', Mol. Psychiatry 2004, 9, 151-160.
242. K. Mitrunen, A. Hirvonen, 'Molecular epidemiology of sporadic breast cancer - The role of polymorphic genes involved in oestrogen biosynthesis and metabolism', Mutat. Res. 2003, 544, 9-41.
243. R. M. Weinshilboum, 'Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase', Cell. Mol. Neurobiol. 2006, 26, 539-561.
244. L. Hosak, 'Role of the COMT gene Val158 Met polymorphism in mental disorders: a review', Eur. Psychiatry 2007, 22, 276-281.
245. L. Lennard, J. A. Vanloon, R. M. Weinshilboum, 'Pharmacogenetics of acute azathioprine toxicity - Relationship to thiopurine methyltransferase genetic polymorphism', Clin. Pharmacol. Ther. 1989, 46, 149-154.
246. H. Wu, J. R. Horton, K. Battaile, A. Allali-Hassani, F. Martin, H. Zeng, P. Loppnau, M. Vedadi, A. Bochkarev, A. N. Plotnikov, X. D. Cheng, 'Structural basis of allele variation of human thiopurine-S-methyltransferase', Proteins 2007, 67, 198-208.
247. R. Weinshilboum, 'Genomic medicine - Inheritance and drug response', N. Engl. J. Med. 2003, 348, 529-537.
248. E. Schaeffeler, C. Fischer, D. Brockmeier, D. Wernet, K. Moerike, M. Eichelbaum, U. M. Zanger, M. Schwab, 'Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German Caucasians and identification of novel TPMT variants', Pharmacogenetics 2004, 14, 407-417.
249. C. V. Preuss, T. C. Wood, C. L. Szumlanski, R. B. Raftogianis, D. M. Otterness, B. Girard, M. C. Scott, R. M. Weinshilboum, 'Human histamine N-methyltransferase pharmacogenetics: Common genetic polymorphisms that alter activity', Mol. Pharmacol. 1998, 53, 708-717.
250. W. O. Pereira, A. S. Paiva, J. W. Queiroz, L. Toma, C. P. Dietrich, H. B. Nader, S. M. B. Jeronimo, 'Genetic polymorphism in the sulfotransferase SULT1A1 gene in cancer', Cancer Genet. Cytogenet. 2005, 160, 55-60.
251. B. Ning, S. Nowell, C. Sweeney, C. B. Ambrosone, S. Williams, X. Miao, G. Liang, D. Lin, A. Stone, D. L. Ratnasinghe, M. Manjanatha, N. P. Lang, F. F. Kadlubar, 'Common genetic polymorphisms in the 5′-flanking region of the SULT1A1 gene: haplotypes and their association with platelet enzymatic activity', Pharmacogenet. Genomics 2005, 15, 465-473.
252. M. F. Hou, S. T. Chen, J. C. Chen, K. T. Yeh, T. P. Lee, C. M. Chen, M. C. Shih, C. C. Lin, J. G. Chang, 'Sulfotansferase 1A2*2 is a risk factor for early-onset breast cancer', Int. J. Mol. Med. 2002, 10, 609-612.
253. N. Hempel, N. Gamage, J. L. Martin, M. E. McManus, 'Human cytosolic sulfotransferase SULT1A1', Int. J. Biochem. Cell Biol. 2007, 39, 685-689.
254. S. Nowell, C. N. Falany, 'Pharmacogenetics of human cytosolic sulfotransferases', Oncogene 2006, 25, 1673-1678.
255. R. B. Raftogianis, T. C. Wood, D. M. Otterness, J. A. Van Loon, R. M. Weinshilboum, 'Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype', Biochem. Biophys. Res. Commun. 1997, 239, 298-304.
256. S. Ozawa, M. Shimizu, T. Katoh, A. Miyajima, Y. Ohno, Y. Matsumoto, M. Fukuoka, Y. M. Tang, N. P. Lang, F. F. Kadlubar, 'Sulfating activity and stability of cDNA-expressed allozymes of human phenol sulfotransferase, ST1A3*1 ((213)Arg) and ST1A3*2 ((213)His), both of which exist in Japanese as well as Caucasians', J. Biochem. (Tokyo). 1999, 126, 271-277.
257. H. Glatt, W. Meinl, 'Pharmacogenetics of soluble sulfotransferases (SULTs)', Naunyn-Schmiedeberg's Arch. Pharmacol. 2004, 369, 55-68.
258. E. J. Carlini, R. B. Raftogianis, T. C. Wood, F. Jin, W. Zheng, T. R. Rebbeck, R. M. Weinshilboum, 'Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects', Pharmacogenetics 2001, 11, 57-68.
259. R. B. Raftogianis, T. C. Wood, R. M. Weinshilboum, 'Human phenol sulfotransferases SULT1A2 and SULT1A1: genetic polymorphisms, allozyme properties, and human liver genotype-phenotype correlations', Biochem. Pharmacol. 1999, 58, 605-616.
260. S. Nagar, S. Walther, R. L. Blanchard, 'Sulfotransferase (SULT) 1A1 polymorphic variants*1,*2, and*3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation', Mol. Pharmacol. 2006, 69, 2084-2092.
261. Y. Ji, I. Moon, J. Zlatkovic, O. E. Salavaggione, B. A. Thomae, B. W. Eckloff, E. D. Wieben, D. J. Schaid, R. M. Weinshilboum, 'Human hydroxysteroid sulfotransferase SULT2B1 pharmacogenomics: Gene sequence variation and functional genomics', J. Pharmacol. Exp. Ther. 2007, 322, 529-540.
262. M. A. Hildebrandt, D. P. Carrington, B. A. Thomae, B.W. Eckloff, D. J. Schaid, V. C. Yee, R. M. Weinshilboum, E. D. Wieben, 'Genetic diversity and function in the human cytosolic sulfotransferases', Pharmacogenomics J. 2007, 7, 133-143.
263. L. C. Wienkers, T. G. Heath, 'Predicting in vivo drug interactions from in vitro drug discovery data', Nat. Rev. Drug Discovery 2005, 4, 825-833.
264. C. Guillemette, 'Pharmacogenomics of human UDP-glucuronosyltransferase enzymes', Pharmacogenomics J. 2003, 3, 136-158.
265. F. Innocenti, W. Q. Liu, P. X. Chen, A. A. Desai, S. Das,M. J. Ratain, 'Haplotypes of variants in the UDP-glucuronosyltransferase 1A9 and 1A1 genes', Pharmacogenet. Genomics 2005, 15, 295-301.
266. S. Nagar, R. L. Blanchard, 'Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan', Drug Metab. Rev. 2006, 38, 393-409.
267. J. O. Miners, R. A. McKinnon, P. I. Mackenzie, polymorphisms of UDP-glucuronosyl-transferases and their functional significance', Toxicology 2002, 181, 453-456.
268. S. Krishnaswamy, Q. Hao, A. Al-Rohaimi, L. M. Hesse, L. L. von Moltke, D. J. Greenblatt, M. H. Court, 'UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 5′-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation', J. Pharmacol. Exp. Ther. 2005, 313, 1331-1339.
269. S. Krishnaswamy, Q. Hao, A. Al-Rohaimi, L. M. Hesse, L. L. von Moltke, D. J. Greenblatt, M. H. Court, 'UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S)', J. Pharmacol. Exp. Ther. 2005, 313, 1340-1346.
270. S. Nagar, J. J. Zalatoris, R. L. Blanchard, 'Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells', Pharmacogenetics 2004, 14, 487-499.
271. I. Martineau, A. Tchernof, A. Bélanger, acid residue ILE211 is essential for the enzymatic activity of human UDP-glucuronosyltransferase 1A10 (UGT1A10)', Drug Metab. Dispos. 2004, 32, 455-459.
272. C. Guillemette, J. K. Ritter, D. J. Auyeung, F. K. Kessler, D. E. Housman, 'Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: Functional consequences of three novel missense mutations in the human UGT1A7 gene', Pharmacogenetics 2000, 10, 629-644.
273. M. Ciotti, A. Marrone, C. Potter, I. S. Owens, 'Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications', Pharmacogenetics 1997, 7, 485-495.
274. K. Chen, M. J. Jin, Y. M. Zhu, Q. T. Jiang,W. P. Yu, X. Y. Ma, K. Y. Yao, 'Genetic polymorphisms of the uridine diphosphate glucuronosyltransferase 1A7 and colorectal cancer risk in relation to cigarette smoking and alcohol drinking in a Chinese population', J. Gastroenterol. Hepatol. 2006, 21, 1036-1041.
275. Y. Chen, G. E. Kuehl, J. Bigler, C. F. Rimorin, Y. Schwarz, D. D. Shen, J. W. Lampe, 'UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin', Pharmacogenet. Genomics 2007, 17, 571-579.
276. Y. K. Chen, S. Q. Chen, X. Li, X. W. Wang, S. Zeng, 'Genetic variants of human UGT1A3: Functional characterization and frequency distribution in a Chinese Han population', Drug Metab. Dispos. 2006, 34, 1462-1467.
277. M. Iwai, Y. Maruo, M. Ito, K. Yamamoto, H. Sato, Y. Takeuchi, 'Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity', J. Hum. Genet. 2004, 49, 123-128.
278. U. Ehmer, A. Vogel, J. K. Schutte, B. Krone, M. P. Manns, C. P. Strassburg, 'Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4', Hepatology 2004, 39, 970-977.
279. S. Nagar, R. P. Remmel, 'Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer', Oncogene 2006, 25, 1659-1672.
280. Z. Zheng, J. Y. Park, C. Guillemette, S. P. Schantz, P. Lazarus, 'Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk', J. Natl. Cancer Inst. 2001, 93, 1411-1418.
281. L. Villeneuve, H. Girard, L. C. Fortier, J. F. Gagne, C. Guillemette, 'Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs', J. Pharmacol. Exp. Ther. 2003, 307, 117-128.
282. E. Levesque, M. Beaulieu, M. D. Green, T. R. Tephly, A. Bélanger, D. W. Hum, 'Isolation and characterization of UGT2B15(Y-85): A UDP-glucuronosyltransferase encoded by a polymorphic gene', Pharmacogenetics 1997, 7, 317-325.
283. M. H. Court, Q. Hao, S. Krishnaswamy, T. Bekaii-Saab, A. Al-Rohaimi, L. L. von Moltke, D. J. Greenblatt, 'UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver', J. Pharmacol. Exp. Ther. 2004, 310, 656-665.
284. E. Levesque, D. Turgeon, J. S. Carrier, V. Montminy, M. Beaulieu, A. Belanger, 'Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase', Biochemistry (Moscow). 2001, 40, 3869-3881.
285. L. Iyer, S. Das, L. Janisch, M. Wen, J. Ramirez, T. Karrison, G. F. Fleming, E. E. Vokes, R. L. Schilsky, M. J. Ratain, 'UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity', Pharmacogenomics J. 2002, 2, 43-47.
286. D. A. Price Evans, K. A. Manley, V. A. Mckusick, 'Genetic control of isoniazid metabolism in man', Br. Med. J. 1960, 2, 485-491.
287. D. A. Price Evans, P. B. Storey, F. B. Wittstadt, K. A. Manley, 'Determination of the isoniazid inactivator phenotype', Am. Rev. Respir. Dis. 1960, 82, 853-861.
288. E. Rey, D. Gendrel, J. M. Treluyer, A. Tran, A. Pariente-Khayat, P. d'Athis, G. Pons, 'Isoniazid pharmacokinetics in children according to acetylator phenotype', Fundam. Clin. Pharmacol. 2001, 15, 355-359.
289. R. L. F. Teixeira, A. B. Miranda, A. G. Pacheco, M. Q. P. Lopes, J. Fonseca-Costa, M. F. Rabahi, H. M. Melo, A. L. Kritski, F. C. Q. Mello, P. N. Suffys, A. R. Santos, 'Genetic profile of the arylamine N-acetyltransferase 2 coding gene among individuals from two different regions of Brazil', Mutat. Res. 2007, 624, 31-40.
290. 'Consensus Arylamine N-Acetyltransferase (NAT) Gene Nomenclature' homepage, http://louisville.edu/medschool/pharmacology/NAT.html.
291. Y. Zang, M. A. Doll, S. Zhao, J. C. States, D. W. Hein, 'Functional characterization of singlenucleotide polymorphisms and haplotypes of human N-acetyltransferase 2', Carcinogenesis 2007, 28, 1665-1671.
292. W.W. Weber, D. W. Hein, 'N-Acetylation pharmacogenetics', Pharmacol. Rev. 1985, 37, 25-79.
293. D.W. Hein, A. J. Fretland, M. A. Doll, 'Effects of single nucleotide polymorphisms in human N-acetyltransferase 2 on metabolic activation (O-acetylation) of heterocyclic amine carcinogens', Int. J. Cancer 2006, 119, 1208-1211.
294. E. Reszka, W. Wasowicz, J. Gromadzinska, 'Genetic polymorphism of xenobiotic metabolising enzymes, diet and cancer susceptibility', Br. J. Nutr. 2006, 96, 609-619.
295. L. Le Marchand, J. H. Hankin, L. M. Pierce, R. Sinha, P. V. Nerurkar, A. A. Franke, L. R. Wilkens, L. N. Kolonel, T. Donlon, A. Seifried, L. J. Custer, A. Lum-Jones, W. Chang, 'Well-done red meat, metabolic phenotypes and colorectal cancer in Hawaii', Mutat. Res. 2002, 506, 205-214.
296. L. M. Morton, M. Schenk, D. W. Hein, S. Davis, S. H. Zahm, W. Cozen, J. R. Cerhan, P. Hartge, R. Welch, S. J. Chanock, N. Rothman, S. S. Wang, 'Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma', Pharmacogenet. Genomics 2006, 16, 537-545.
297. K. Yokogawa, T. Nakaharu, J. Ishizaki, E. Ozaki, Y. Takeda, H. Mabuchi, R. Matsushita, K. Kimura, E. Nakashima, F. Ichimura, K. Miyamoto, 'Kinetic phenotypic diagnosis of N-acetylation polymorphism in patients based on ratio of urinary metabolites of salicylazosulfapyridine', Int. J. Pharm. 2001, 229, 183-191.
298. D.W. Hein, M. A. Doll, T. D. Rustan, K. Gray, Y. Feng, R. J. Ferguson, D. M. Grant, 'Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases', Carcinogenesis 1993, 14, 1633-1638.
299. I. Cascorbi, J. Brockmoller, S. Bauer, T. Reum, I. Roots, 'NAT2*12A (803A→G) codes for rapid arylamine N-acetylation in humans', Pharmacogenetics 1996, 6, 257-259.
300. A. Gulaid, I. M. James, C. M. Kaye, O. R. Lewellen, E. Roberts, M. Sankey, J. Smith, R. Templeton, R. J. Thomas, 'Lack of correlation between acetylator status and the production of the acetyl metabolite of acebutolol in man', Br. J. Clin. Pharmacol. 1978, 5, 261-262.
301. A. K. Daly, 'Pharmacogenetics of the major polymorphic metabolizing enzymes', Fundam. Clin. Pharmacol. 2003, 17, 27-41.
302. H. M. Bolt, R. Thier, 'Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology', Curr. Drug Metab. 2006, 7, 613-628.
303. A. Torkaman-Boutorabi, M. Hoormand, N. Naghdi, M. Bakhshayesh, I. Milanian, 'Genotype and allele frequencies of N-acetyltransferase 2 and glutathione S-transferase in the Iranian population', Clin. Exp. Pharmacol. Physiol. 2007, 34, 1207-1211.
304. S. L. Zhong, S. F. Zhou, X. Chen, M. Huang, 'Rapid determination of common mutations in glutathione S-transferase gene by PCR-based methods in healthy Chinese', Clin. Chim. Acta 2006, 364, 205-208.
305. J. Schneider, U. Bernges, M. Philipp, H. J. Woitowitz, 'GSTM1, GSTT1, and GSTP1 polymorphism and lung cancer risk in relation to tobacco smoking', Cancer Lett. 2004, 208, 65-74.
306. I. P. Hall, M. Pirmohamed, 'Pharmacogenomic', Informa Healthcare, London, 2006.
307. 'Guidance for Industry - Pharmacogenomic Data Submissions homepage, www.fda.gov/cber/gdlns/pharmdtasub.pdf.
308. 'Genomics at FDA homepage, http://www.fda.gov/cder/genomics/.
309. 'European Medicines Agency: Pre-authorisation Evaluation of Medicines for Human Use' homepage, www.emea.europa.eu/pdfs/human/pharmacogenetics/ 12851706enfin.pdf.
310. 'European Medicines Agency: Medicines and Emerging Science homepage, http://www.emea.europa.eu/htms/human/mes/emergingtechnologies.htm.
311. A. Mode, J. A. Gustafsson, 'Sex and the liver - A journey through five decades', Drug Metab. Rev. 2006, 38, 197-207.
312. P. A. Thurmann, 'Sex-specific differences in drug treatment (German)', Ther.Umsch. 2007, 64, 325-329.
313. J. B. Schwartz, 'The influence of sex on pharmacokinetics', Clin. Pharmacokinet. 2003, 42, 107-121.
314. G. D. Anderson, 'Sex differences in drug metabolism: cytochrome P-450 and uridine diphosphate glucuronosyltransferase', J. Gen. Specif. Med. 2002, 5, 25-33.
315. B. Meibohm, I. Beierle, H. Derendorf, 'How important are gender differences in pharmacokinetics?', Clin. Pharmacokinet. 2002, 41, 329-342.
316. P. L. Bonate, 'Gender-related differences in xenobiotic metabolism', J. Clin. Pharmacol. 1991, 31, 684-690.
317. P. G. Zaphiropoulos, A. Mode, G. Norstedt, J. A. Gustafsson, 'Regulation of sexual differentiation in drug and steroid metabolism', Trends Pharmacol. Sci. 1989, 10, 149-153.
318. G. J. Mulder, 'Sex differences in drug conjugation and their consequences for drug toxicity - Sulfation, glucuronidation and gluthatione conjugation', Chem.-Biol. Interact. 1986, 57, 1-15.
319. W. J. Tamminga, J. Wemer, B. Oosterhuis, J. Wieling, B. Wilffert, L. F. M. H. de Leij, R. A. de Zeeuw, J. H. G. Jonkman, 'CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences', Eur. J. Clin. Pharmacol. 1999, 55, 177-184.
320. M. M. Cotreau, L. L. von Moltke, D. J. Greenblatt, 'The influence of age and sex on the clearance of cytochrome P450 3A substrates', Clin. Pharmacokinet. 2005, 44, 33-60.
321. M. Gandhi, F. Aweeka, R. M. Greenblatt, T. F. Blaschke, 'Sex differences in pharmacokinetics and pharmacodynamics', Annu. Rev. Pharmacol. Toxicol. 2004, 44, 499-523.
322. R. Wolbold, K. Klein, O. Burk, A. K. Nussler, P. Neuhaus, M. Eichelbaum, M. Schwab, U. M. Zanger, 'Sex is a major determinant of CYP3A4 expression in human liver', Hepatology 2003, 38, 978-988.
323. D. J. Waxman, C. O'Connor, 'Growth hormone regulation of sex-dependent liver gene expression', Mol. Endocrinol. 2006, 20, 2613-2629.
324. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris, H. Varmus, 'EGF receptor gene mutations are common in lung cancers from 'nerve smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib', Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 13306-13311.
325. H. G. Xie, F. W. Frueh, 'Pharmacogenomics steps toward personalized medicine', Personalized Med. 2005, 2, 325-337.
326. 'FDA: Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels homepage', http://www.fda.gov/cder/genomics/ genomic_biomarkers_table.htm.
327. E. J. Sirot, J. W. van der Velden, K. Rentsch, C. B. Eap, P. Baumann, 'Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance', Drug Safety 2006, 29, 735-768.
328. M. Hiratsuka, A. Ebisawa, K. Sakuyama, Y. Matsubara, S. Kure, Y. Soya, Y. Konno, T. Sasaki, A. Kishiba, M. Mizugaki, 'Competitive allele-specific short oligonucleotide hybridization (CASSOH) with enzyme-linked immunosorbent assay (ELISA) for the detection of pharmacogenetic single nucleotide polymorphisms (SNPs)', J. Biochem. Biophys. Methods 2006, 67, 87-94.
329. J. F. Solus, B. J. Arietta, J. R. Harris, D. P. Sexton, J. Q. Steward, C. McMunn, P. Ihrie, J. M. Mehall, T. L. Edwards, E. P. Dawson, 'Genertic variation in eleven Phase I drug metabolism genes in an ethnically diverse population', Pharmacogenomics 2004, 5, 895-931.
330. R. F. Frye, G. R. Matzke, A. Adedoyin, J. A. Porter, R. A. Branch, 'Validation of the five-drug 'Pittsburgh cocktail' approach for assessment of selective regulation of drug-metabolizing enzymes', Clin. Pharmacol. Ther. 1997, 62, 365-376.
331. M. Christensen, K. Andersson, P. Dalen, R. A. Mirghani, G. J. Muirhead, A. Nordmark, G. Tybring, A. Wahlberg, U. Yasar, L. Bertilsson, 'The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes', Clin. Pharmacol. Ther. 2003, 73, 517-528.
332. W. Kalow, K. Genest, 'A method for the detection of atypical forms of human serum cholinesterase - Determination of dibucaine numbers', Can. J. Biochem. Physiol. 1957, 35, 339-346.
333. H. Harris, M. Whittaker, 'Differential inhibition of human serum cholinesterase with fluoride - Recognition of 2 new phenotypes', Nature 1961, 191, 496-498.